Novartis company profile 29.01.2021

Novartis: Reimagining Medicine for Healthy & Productive Filipinos






OUR PURPOSE

We reimagine medicine to improve and extend the lives of Filipinos. We discover breakthrough treatments and find new ways to deliver them to Filipinos.




Delivering Transformative Innovation Unleashing the Power of our People

Addressing the evolving needs of Filipino patients through the following Providing employment to Filipinos, and regional leadership
therapeutic areas: exposure to local talents
Developing local scientists through the Next Generation
Scientist program
Cardiovascular & Introduced Omni-channel medical engagement to keep
Metabolism Neuroscience Ophthalmology
healthcare professionals safe during the pandemic


Our Collaborations
Immunology & Oncology & Respiratory
Dermatology Hematology Strengthening local Collaboration to Supported nationwide
health systems through Preserve Sight, a COVID-19 response
the establishment of public-private sector with a focus on
Through various access programs, Novartis helps 10,000 underprivileged Filipino Heart Failure Clinics, coalition to help protecting frontline
patients receive effective treatments, including 2100 oncology and hematology patients Service Delivery address blindness and health workers, patients
with advanced breast cancer, thalassemia and other cancers Network, Universal vision impairment and associates, and
Health Care Forums among Filipinos through expanding testing and
Introduced emerging market brands for Heart Failure and Psoriasis and Hospital patient education and treatment capacity of
CEO Forums vision screening healthcare system
With PhilHealth and accredited hospitals, provides Kidney Transplant Package to
qualified PhilHealth members
Serving as the generic pharmaceuticals division of Novartis, offers
affordable, high-quality generic medicines and biosimilars to Filipino patients Co-created the Progressive Alliance
Towards Healthy Workplaces (PATHw), a
In partnership with the World Health Organization, Novartis provides the Department Pan-Asia coalition of respected Human
of Health with anti-malaria medicine (Coartem) at cost to support the National Malaria Resources and business leaders who are
Control Program committed to leading a change for
healthier workplaces and behaviors
To help address mobility limitations posed by the community quarantine, we partnered
with GBSL and MedGrocer to provide home delivery of patients' medicines


OUR IMPACT



Research & Development Economic and Social



Established Centers of Excellence for Clinical Trials
in various hospitals and research institutes GDP Employment

Invested over PHP 104 million Contributed more GDP to the Created more jobs for Filipinos in 2019
in clinical trials in 2019 economy in 2019 Created 9,517

R&D intensity in 2019 was 4%, exceeding PHP 8 local jobs
the European Union target of 3% billion


Active recruiting trials in cardiovascular medicine, Employed 488
Filipino associates
immunology and dermatology, respiratory, neurology,
nephrology, ophthalmology and oncology

Collaborated with Asian Eye Institute to generate Social
local health economics and outcomes research
Contributed PHP 5.2 billion through
products and human capital in 2019
Published the Migraine Burden of Disease study in
the Journal of Headache and Pain Novartis’ products: Achieved 16,277
PHP 4.6 billion quality-adjusted life years


Human capital: (QALYs) for 1 million
PHP 615 million patients across 52 brands




Awards & Recognition

Special Recognition for Commitment to Leadership, Aon Best Employers program Outstanding Healthy Lifestyle Advocacy Award, Department of Health
Special citation from the Department of Health and Office of the President for Agora Award for Outstanding Achievement in Advocacy Marketing,
contribution to nationwide COVID-19 response Philippine Marketing Association


Reference: WifoR Institute, “The Social Impact of Novartis Innovative Medicines and Sandoz Products in Philippines in 2019”. Data on file.

www.novartis.com.ph